This is the first and only conference exclusively focusing on ADC payloads, helping you to reimagine the medicinal chemistry of ...

The 3rd Obesity & Weight Loss Drug Development Summit is the place to be for experts in weight loss drug development tackling ...

A digital therapeutic (DTx) for attention deficit hyperactivity disorder (ADHD) developed by Akili has been approved in Japan ...

Bullous pemphigoid (BP), which has no FDA-approved targeted therapies, leads to reddening of the skin and the formation of ...

Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...

The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

The text of the bill is vanishingly short and does not give any indication of the drugs that might be prescribed by AIs or ...

TauRx Pharma's effort to bring a tau-targeting drug for Alzheimer's disease (AD) to market has been a marathon, with a number of setbacks over the years, but the company reckons it may finally be ...

After much deliberation, the FDA has granted accelerated approval for Biogen’s tofersen for an ultra-rare form of the neurodegenerative disease amyotrophic lateral sclerosis, associated with a ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Just a few months after buying Timber Pharma, LEO Pharma has revealed that the main drug it acquired as part of the deal has failed a phase 3 trial. Timber's lead candidate TMB-001 for rare skin ...

The 6th Cytokine-Based Drug Development Summit (May 15-16 in Boston) returns as the only industry focused conference that ...